Brimotale Plus Eye Drop contains Brimonidine 0.2% w/v, a selective alpha-2 adrenergic agonist used to reduce elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension. Its reliable formulation ensures effective and well-tolerated long-term ophthalmic therapy.
The eye drop works by decreasing aqueous humor production and enhancing uveoscleral outflow, helping to maintain controlled eye pressure and protect the optic nerve, thereby supporting sustained visual health.
From a business perspective, Brimotale Plus Eye Drop is a high-demand anti-glaucoma ophthalmic product, widely prescribed in eye hospitals, ophthalmology clinics, and specialty glaucoma centers, ensuring consistent prescriptions and repeat sales.
Adding Brimotale Plus Eye Drop to your portfolio strengthens the ophthalmic anti-glaucoma segment, offering long-term growth, strong prescriber trust, and enhanced portfolio credibility for PCD pharma franchise partners.